Popular Pre-Market Trades in US Stocks

PS, down 20.00% in pre-market, no significant news recently. Trading is active, with clear capital flow. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Livewire, down 16.67% in pre-market, no significant news recently. Trading is active, with clear capital flow. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Top Gainers in Pre-Market US Stocks

Nature's Way Pharmaceuticals up 258.45% in pre-market. Based on recent key news:

1. On June 26, Nature's Way Pharmaceuticals announced a strategic acquisition of Best Praise International Limited, aiming to expand its drug patent portfolio. The acquisition involves a stock transaction valued at $10.75 million, with Best Praise holding five drug development-related patents in China. This news significantly boosted the stock price. Source: Reuters

2. On June 27, Universe Pharmaceuticals announced that the acquisition of Best Praise is expected to be completed in the third quarter of 2026. This news further enhanced market confidence in the company's future development. Source: WSJ

3. On June 27, the market reacted positively to the acquisition news from Nature's Way Pharmaceuticals, with the stock price significantly rising in pre-market. Investors expressed optimism about the company's strategy to expand its drug patent portfolio. Source: GlobeNewswire The pharmaceutical industry has performed strongly recently, with clear policy support.

Decoy Therapeutics up 122.36% in pre-market. Based on recent key news:

1. On June 26, Decoy Therapeutics announced a private placement financing of up to $21 million. Following this announcement, market confidence in the company's future development surged, driving the stock price significantly higher.

2. On June 26, Decoy Therapeutics launched its innovative product Designable Multi-Antivirals (D-MAVs™) in Houston. This product aims to target common viral mechanisms across multiple virus families, showcasing the company's leading position in antiviral treatments and further boosting investor confidence.

3. On June 27, the company issued a forward-looking statement indicating that despite financing and product development risks, it is confident about future performance. The optimistic expectations of investors regarding the company's prospects also contributed to the stock price increase. The biotechnology industry has performed strongly recently, with significant capital inflow.

Inlif up 49.89% in pre-market. Based on recent key news:

1. On June 26, TipRanks' AI analyst Spark rated INLF stock as neutral, with a target price of $0.05. The analyst pointed out that financial performance is expected to deteriorate sharply in 2025, including loss results and negative cash flow, while the technical aspect is very weak, with momentum severely oversold and the stock price far below major moving averages, leading to stock price volatility Recent market volatility has intensified, and attention must be paid to risks